In order to increase the confidence in the conclusion that flumioxazin does not have endocrine disrupting properties, the applicant should provide an updated assessment, in accordance with point 2.2(b) of Annex II to Regulation (EC) No 1107/2009 concerning the criteria laid down in points 3.6.5 and 3.8.2 of Annex II to that Regulation.
Recital 18, Regulation (EU) 2022/43
In forcesince 13 Jan 2022